Dave Suchon
- 20+ years in Canadian pharma
- 12 years in executive leadership at Novo Nordisk
- Led the Health Canada approval of Ozempic®
- Biochemistry study and research in protein chemistry
- Pharma regulatory lawyer and patent litigator
About Vimy Pharma
A national pharmaceutical company built to produce an abundant, reliable supply of high-quality, affordable essential medicines.
Vimy Pharma exists to give Canadians a reliable, affordable, Canadian-manufactured supply of essential medicines, starting with generic semaglutide.
We are a national company. Headquartered in Toronto, we developed our first batches in the GTA and will now manufacture at multiple Canadian sites.
Our team brings decades of experience taking medicines through Health Canada, including the original Canadian approval of Ozempic®. Today we have two generic submissions under way, referencing Ozempic® and Wegovy®.
Making essential medicines at home builds resilience into Canada’s healthcare system: reliable supply, skilled Canadian jobs, and value that stays in the country.
Manufactured in CanadaCanadians living with type 2 diabetes1
Canadians living with obesity2
Canadians currently treated with injectable semaglutide3
More than 2 million Canadian adults are interested in a GLP-1 medication but are not taking one, many because of cost.4
Vimy-semaglutide and Vimy-semaglutide (WT) will be made at multiple sites across Canada, including on a Steriline vial production line at Canada’s Critical Medicines Production Centre in Edmonton, Alberta.
Manufacturing here, to Health Canada’s rigorous standards, gives Canadians a domestic source of a W.H.O. essential medicine, with an initial capacity of 10 million units a year and plans to quadruple it over the coming years.1
Steriline vial production line for Vimy-semaglutide and Vimy-semaglutide (WT) at Canada’s Critical Medicines Production Centre.
Canada’s pharmaceutical trade deficit has nearly tripled in under a decade. Over time, we believe increased domestic production can substantially narrow it, and keep more intellectual property and economic value in Canada.
Canada’s pharmaceutical trade deficit, C$ billions
Source: Statistics Canada Trade Data Online; ISED Canadian Industry Statistics (NAICS 32541), 2016–2025.
Vimy Pharma’s full profit margin will be taxed by the CRA.
High-value life sciences employment in Ontario, Alberta and beyond.
Contributing to Canada’s advanced manufacturing base for essential medicines.
Health Canada has proposed a pilot to prioritize generic submissions involving domestic manufacturing.2